- Germany
- /
- Healthcare Services
- /
- XTRA:FRE
Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Fresenius SE KGaA fair value estimate is €44.79
- Current share price of €27.59 suggests Fresenius SE KGaA is potentially 38% undervalued
- The €35.38 analyst price target for FRE is 21% less than our estimate of fair value
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Fresenius SE & Co. KGaA (ETR:FRE) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Don't get put off by the jargon, the math behind it is actually quite straightforward.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
Check out our latest analysis for Fresenius SE KGaA
The Method
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | |
Levered FCF (€, Millions) | €2.20b | €2.58b | €2.45b | €2.54b | €2.01b | €1.91b | €1.85b | €1.81b | €1.78b | €1.77b |
Growth Rate Estimate Source | Analyst x7 | Analyst x7 | Analyst x4 | Analyst x3 | Analyst x2 | Est @ -4.69% | Est @ -3.24% | Est @ -2.22% | Est @ -1.50% | Est @ -1.01% |
Present Value (€, Millions) Discounted @ 7.9% | €2.0k | €2.2k | €1.9k | €1.9k | €1.4k | €1.2k | €1.1k | €988 | €902 | €828 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = €14b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.2%. We discount the terminal cash flows to today's value at a cost of equity of 7.9%.
Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = €1.8b× (1 + 0.2%) ÷ (7.9%– 0.2%) = €23b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €23b÷ ( 1 + 7.9%)10= €11b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is €25b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of €27.6, the company appears quite undervalued at a 38% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
The Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Fresenius SE KGaA as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.9%, which is based on a levered beta of 1.299. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Fresenius SE KGaA
- Debt is well covered by earnings.
- Dividends are covered by earnings and cash flows.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Healthcare market.
- Annual earnings are forecast to grow faster than the German market.
- Good value based on P/E ratio and estimated fair value.
- Debt is not well covered by operating cash flow.
- Revenue is forecast to grow slower than 20% per year.
Moving On:
Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. What is the reason for the share price sitting below the intrinsic value? For Fresenius SE KGaA, we've put together three fundamental aspects you should consider:
- Risks: You should be aware of the 1 warning sign for Fresenius SE KGaA we've uncovered before considering an investment in the company.
- Future Earnings: How does FRE's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every German stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:FRE
Fresenius SE KGaA
A health care company, provides products and services for chronically ill patients.
Undervalued with adequate balance sheet.